Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688, A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells, Administered Intravenously in Patients With Locally Advanced and/or Metastatic CEA(+) Solid Tumors
Conditions
Interventions
RO6958688
Obinutuzumab
+1 more
Locations
21
United States
Cedars Sinai Medical Center; Samuel-Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
UCLA Cancer Center
Santa Monica, California, United States
University Of Colorado
Aurora, Colorado, United States
Yale Cancer Center; Medical Oncology
New Haven, Connecticut, United States
Dana Farber - Harvard
Boston, Massachusetts, United States
Start Date
December 30, 2014
Primary Completion Date
September 3, 2019
Completion Date
September 3, 2019
Last Updated
April 17, 2020
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06716138
NCT06307795
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions